Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice

Infection and Immunity

Volumn 80, Issue 4, 2012, Pages 1510-1518

  Yu, Hong ^a   Karunakaran, Karuna P ^a   Jiang, Xiaozhou ^a   Shen, Caixia ^a   Andersen, Peter ^b   Brunham, Robert C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AASF ANTIGEN; CYTOPLASM PROTEIN; DDA MONOMYCOLYL GLYCEROL; DDA TREHALOSE 6,6' DIBEHENATE; DIMETHYLDIOCTADECYLAMMONIUMBROMIDE MONOPHOSPHORYL LIPID A; GAMMA INTERFERON; MONATANIDE ISA720 CPG ODN1826; OUTER MEMBRANE PROTEIN; PMPF ANTIGEN; PMPG ANTIGEN; RPLF ANTIGEN; T LYMPHOCYTE ANTIGEN; TC 0420 ANTIGEN; TC 0825 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL VACCINE; DIMETHYLDIOCTADECYLAMMONIUM; IMMUNOLOGICAL ADJUVANT; LIPID A; LIPOPEPTIDE; OMP1 PROTEIN, CHLAMYDIA TRACHOMATIS; PORIN; QUATERNARY AMMONIUM DERIVATIVE; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CHLAMYDIA; CHLAMYDIASIS; CONTROLLED STUDY; FEMALE; GENITAL TRACT INFECTION; IMMUNE RESPONSE; IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; CHLAMYDIA TRACHOMATIS; GYNECOLOGIC DISEASE; HELA CELL; HUMAN; IMMUNIZATION; IMMUNOLOGY; MICROBIOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CHLAMYDIA INFECTIONS; CHLAMYDIA MURIDARUM; CHLAMYDIA TRACHOMATIS; FEMALE; GENITAL DISEASES, FEMALE; HELA CELLS; HUMANS; IMMUNIZATION; INTERFERON-GAMMA; LIPID A; LIPOPEPTIDES; MICE; MICE, INBRED C57BL; PORINS; QUATERNARY AMMONIUM COMPOUNDS; REPRODUCTIVE TRACT INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, SYNTHETIC;

EID: 84860793222     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.06338-11     Document Type: Article

References (43)

1. Aagaard C, et al. 2011. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat. Med. 17:189-194.
2. Agger EM, et al. 2008. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 3:e3116.
3. Andersen CS, et al. 2009. A simple mycobacterial monomycolated glycerol lipid has potent immunostimulatory activity. J. Immunol. 182:424-432.
4. Bilenki L, et al. 2005. NK T cell activation promotes Chlamydia trachomatis infection in vivo. J. Immunol. 175:3197-3206.
5. Brunham RC, Pourbohloul B, Mak S, White R, Rekart ML. 2005. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J. Infect. Dis. 192:1836-1844.
6. Brunham RC, Rey-Ladino J. 2005. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat. Rev. Immunol. 5:149-161.
7. Caldwell HD, Kromhout J, Schachter J. 1981. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect. Immun. 31:1161-1176.
8. Chaganty BK, et al. 2010. Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge. Vaccine 28:2323-2329.
9. Christensen D, et al. 2009. Liposome-based cationic adjuvant formulations (CAF): past, present, and future. J. Liposome Res. 19:2-11.
10. Christensen D, et al. 2007. Cationic liposomes as vaccine adjuvants. Expert Rev. Vaccines 6:785-796.
11. Doolan DL, et al. 2000. HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J. Immunol. 165:1123-1137.
12. Eko FO, et al. 2004. A novel recombinant multisubunit vaccine against Chlamydia. J. Immunol. 173:3375-3382.
13. Finco O, et al. 2011. Approach to discover T-and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines. Proc. Natl. Acad. Sci. U. S. A. 108:9969-9974.
14. Fling SP, et al. 2001. CD8+ T cells recognize an inclusion membraneassociated protein from the vacuolar pathogen Chlamydia trachomatis. Proc. Natl. Acad. Sci. U. S. A. 98:1160-1165.
15. Goodall JC, Yeo G, Huang M, Raggiaschi R, Gaston JS. 2001. Identification of Chlamydia trachomatis antigens recognized by human CD4+T lymphocytes by screening an expression library. Eur. J. Immunol. 31: 1513-1522.
16. Grayston JT, Wang SP. 1978. The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Sex. Transm. Dis. 5:73-77.
17. Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P. 2004. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect. Immun. 72:1608-1617.
18. Ioannou XP, Griebel P, Hecker R, Babiuk LA, van Drunen Littel-van den Hurk S. 2002. The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoproteinDplus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J. Virol. 76:9002-9010.
19. Ishikawa E, et al. 2009. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J. Exp. Med. 206:2879-2888.
20. Kari L, et al. 2009. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J. Immunol. 182:8063-8070.
21. Kari L, et al. 10 October 2011. A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates. J. Exp. Med. doi: 10.1084/jem.20111266.
22. Karunakaran KP, et al. 2008. Immunoproteomic discovery of novel T cell antigens from the obligate intracellular pathogen Chlamydia. J. Immunol. 180:2459-2465.
23. Korsholm KS, et al. 2007. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 121:216-226.
24. Li W, et al. 2008. Antigen-specific CD4+ T cells produce sufficient IFNgamma to mediate robust protective immunity against genital Chlamydia muridarum infection. J. Immunol. 180:3375-3382.
25. Morrison SG, Su H, Caldwell HD, Morrison RP. 2000. Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells. Infect. Immun. 68:6979-6987.
26. Nicholls EF, Madera L, Hancock RE. 2010. Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Ann. N. Y. Acad. Sci. 1213: 46-61.
27. Pal S, Peterson EM, de la Maza LM. 2005. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect. Immun. 73:8153-8160.
28. Pal S, Peterson EM, Rappuoli R, Ratti G, de la Maza LM. 2006. Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge. Vaccine 24:766-775.
29. Panigada M, et al. 2002. Identification of a promiscuous T-cell epitope in Mycobacterium tuberculosis Mce proteins. Infect. Immun. 70:79-85.
30. Schoenen H, et al. 2010. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J. Immunol. 184:2756-2760.
31. Seder RA, Hill AV. 2000. Vaccines against intracellular infections requiring cellular immunity. Nature 406:793-798.
32. Singh SR, et al. 2006. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection. Vaccine 24:1213-1224.
33. Stanberry LR, Rosenthal SL. 2005. Progress in vaccines for sexually transmitted diseases. Infect. Dis. Clin. North Am. 19:477-490, xi.
34. Starnbach MN, et al. 2003. An inclusion membrane protein from Chlamydia trachomatis enters the MHC class I pathway and stimulates a CD8+ T cell response. J. Immunol. 171:4742-4749.
35. Starnbach MN, Roan NR. 2008. Conquering sexually transmitted diseases. Nat. Rev. Immunol. 8:313-317.
36. Stothard DR, Toth GA, Batteiger BE. 2003. Polymorphic membrane protein H has evolved in parallel with the three disease-causing groups of Chlamydia trachomatis. Infect. Immun. 71:1200-1208.
37. Su H, Caldwell HD. 1995. CD4+T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract. Infect. Immun. 63:3302-3308.
38. Wang S, Fan Y, Brunham RC, Yang X. 1999. IFN-gamma knockout mice show Th2-associated delayed-type hypersensitivity and the inflammatory cells fail to localize and control chlamydial infection. Eur. J. Immunol. 29:3782-3792.
39. Wang SP, Grayston JT, Alexander ER. 1967. Trachoma vaccine studies in monkeys. Am. J. Ophthalmol. 63(Suppl):1615-1630.
40. Yang X, HayGlass KT, Brunham RC. 1996. Genetically determined differences in IL-10 and IFN-gamma responses correlate with clearance of Chlamydia trachomatis mouse pneumonitis infection. J. Immunol. 156: 4338-4344.
41. Yu H, Jiang X, Shen C, Karunakaran KP, Brunham RC. 2009. Novel Chlamydia muridarum T cell antigens induce protective immunity against lung and genital tract infection in murine models. J. Immunol. 182:1602-1608.
42. Yu H, et al. 2010. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA-TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells. Infect. Immun. 78:2272-2282.
43. Yu H, et al. 2011. Immunization with live and dead Chlamydia muridarum induces different levels of protective immunity in a murine genital tract model: correlation withMHCclass II peptide presentation and multifunctional Th1 cells. J. Immunol. 186:3615-3621.